Form 4: Janux Therapeutics Executive Receives Stock Options and Restricted Stock Units

Byron Robinson, Chief Strategy Officer at Janux Therapeutics, was granted 28,000 restricted stock units and stock options for 98,000 shares.

Summary

• Byron Robinson, the Chief Strategy Officer of Janux Therapeutics, received 28,000 restricted stock units (RSUs) on January 2, 2025.
• These RSUs represent a contingent right to receive one share of Janux Therapeutics common stock each.
• The RSUs will vest in four equal annual installments starting on January 1, 2026.
• Mr. Robinson also received stock options for 98,000 shares of Janux Therapeutics common stock on January 2, 2025.
• The exercise price for these options is $53.24 per share.
• 25% of the options will vest on January 1, 2026, with the remaining options vesting in equal monthly installments over the following three years.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs and stock options to the Chief Strategy Officer aligns his interests with the long-term success of the company.
• The vesting schedule of both the RSUs and stock options encourages long-term commitment from the executive.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry, similar to companies like Amgen, Gilead, and Regeneron.
• The vesting schedules are also typical, with a mix of cliff vesting and monthly vesting over a period of years, aligning with industry norms for long-term incentives.

Stakeholder Impact

• The grant of equity to the Chief Strategy Officer aligns his interests with those of shareholders, potentially leading to increased value creation.

Key Dates

Keywords

stock options, restricted stock units, RSUs, executive compensation, Janux Therapeutics, insider trading, form 4, equity